Logo Image
|Videos|May 28, 2019

What to Expect in June's In the Literature

Section Editor, Monica Mahoney, PharmD, shares a preview of the June issue of Contagion.

So, coming up in In the Literature we have 2 fantastic articles that are looking at how do we dose antibiotics in gram-positive infections. We have 1 focusing on daptomycin — it’s a milligram per kilogram dose – so in our obese patients can we use a fixed dose -- Are our results the same?

Additionally, in vancomycin, using AUC-dosing can we mitigate some of the adverse reactions that we’re seeing when we’re doing q6 or q8 dosing in order to maintain troughs of 15-20.

Related to this article

View more
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Read more
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Read more
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Read more